Analyst Reco. Exelixis, Inc.

Equities

EXEL

US30161Q1040

Delayed Nasdaq Other stock markets 03:48:09 2024-05-21 pm EDT			5-day change	1st Jan Change
21.02 ^USD	-0.17%		+0.17%	-12.36%

May. 20	Exelixis Settles Cabometyx Patent Litigation with Cipla	MT
May. 14	Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target	May. 14	MT
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept	May. 01	MT
Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25	Apr. 11	MT
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating	Feb. 07	MT
Barclays Adjusts Price Target on Exelixis to $25 From $24, Keeps Overweight Rating	Jan. 30	MT
BTIG Starts Exelixis With Buy Rating, $27 Price Target	Dec. 19	MT
Citigroup Initiates Exelixis at Buy Rating With $31 Price Target	Dec. 15	MT
Guggenheim Raises Exelixis' Price Target to $30 From $27, Keeps Buy Rating	23-09-25	MT
JMP Securities Adjusts Price Target on Exelixis to $27 From $24, Maintains Market Outperform Rating	23-08-22	MT
Oppenheimer Adjusts Exelixis Price Target to $29 From $25, Maintains Outperform Rating	23-08-22	MT
SVB Securities Initiates Exelixis With Market Perform Rating, $18 Price Target	23-08-08	MT
Barclays Adjusts Price Target on Exelixis to $24 From $25, Maintains Overweight Rating	23-08-03	MT
Morgan Stanley Adjusts Price Target on Exelixis to $22 From $21, Maintains Equal-Weight Rating	23-08-02	MT
RBC Lifts Exelixis' Price Target to $26 From $25, Keeps Outperform Rating	23-07-07	MT
Morgan Stanley Trims Price Target on Exelixis to $21 From $22, Maintains Equalweight Rating	23-04-12	MT
Wells Fargo Starts Exelixis at Overweight With $23 Price Target	23-03-09	MT
RBC Lowers Exelixis Price Target to $25 From $27, Maintains Outperform Rating	23-02-08	MT
Credit Suisse Starts Exelixis at Outperform With $29 Price Target	23-01-26	MT
JMP Securities Adjusts Price Target on Exelixis to $24 From $25, Maintains Market Outperform Rating	23-01-19	MT
Oppenheimer Adjusts Exelixis Price Target to $25 From $27, Maintains Outperform Rating	23-01-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Exelixis, Inc.

Equities

EXEL

US30161Q1040

Analyst Reco.

Filters